Aytu BioPharma Files 10-Q, Reports Q3 2025 Financials
Ticker: AYTU · Form: 10-Q · Filed: May 14, 2025 · CIK: 1385818
| Field | Detail |
|---|---|
| Company | Aytu Biopharma, Inc (AYTU) |
| Form Type | 10-Q |
| Filed Date | May 14, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, warrants
TL;DR
AYTU Q3 2025 10-Q filed. Current assets $6.17M, current liabilities $5.97M. Warrants exercised.
AI Summary
Aytu BioPharma, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported $6,170,162 in current assets and $5,972,638 in current liabilities. A significant event during the quarter was the exercise of 176,000 Tranche B Pre-Funded Warrants at a price of $0.0001 per share.
Why It Matters
This filing provides investors with a quarterly update on Aytu BioPharma's financial health and operational activities, including details on warrant exercises which can impact share structure.
Risk Assessment
Risk Level: medium — The company's financial performance and the impact of warrant exercises on its share structure present medium-term risks.
Key Numbers
- $6.17M — Current Assets (As of March 31, 2025)
- $5.97M — Current Liabilities (As of March 31, 2025)
- 176,000 — Tranche B Pre-Funded Warrants Exercised (During Q1 fiscal 2025)
Key Players & Entities
- AYTU BIOPHARMA, INC (company) — Filer
- 20250331 (date) — Reporting period end date
- 6,170,162 (dollar_amount) — Current assets
- 5,972,638 (dollar_amount) — Current liabilities
- 176,000 (dollar_amount) — Number of Tranche B Pre-Funded Warrants exercised
- 0.0001 (dollar_amount) — Exercise price per share for warrants
FAQ
What was the total value of current assets reported by Aytu BioPharma as of March 31, 2025?
Aytu BioPharma reported total current assets of $6,170,162 as of March 31, 2025.
What were the total current liabilities for Aytu BioPharma for the period ending March 31, 2025?
The company reported total current liabilities of $5,972,638 for the period ending March 31, 2025.
How many Tranche B Pre-Funded Warrants were exercised in the first quarter of fiscal 2025?
176,000 of the Tranche B Pre-Funded Warrants were exercised during the first quarter of fiscal 2025.
At what price were the Tranche B Pre-Funded Warrants exercised?
The Tranche B Pre-Funded Warrants were exercised at a price of $0.0001 per share.
What is the fiscal year end for Aytu BioPharma?
Aytu BioPharma's fiscal year ends on June 30.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 14, 2025 regarding AYTU BIOPHARMA, INC (AYTU).